American biopharmaceutical company in Cambridge, Massachusetts, founded in 2007 and listed on Nasdaq, focused on kidney disease. Develops and markets medicines for anaemia due to chronic kidney disease, including vadadustat, a hypoxia inducible factor prolyl hydroxylase inhibitor sold as Vafseo, and the phosphate binder ferric citrate sold as Auryxia, and runs its own clinical development and commercial operations with manufacturing through contract partners.
No comments available.
Leave your rating & comment